Accessibility Menu
BioVie logo

BioVie(NASDAQ) BIVI

Market Cap$11.46MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2014)-100%
5 Year-100%
1 Year-75%
1 Month-30%
$1.53
+6.99%
+0.10Today
After hours$1.55+$0.02 (+1.31%)
BioVie last closing stock price
MetricPriceDate
Last closeUSD 1.522026-07-31
BioVie stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+10.95%USD 1.372026-07-24
1 month-30.28%USD 2.182026-07-01
3 month-9.52%USD 1.682026-05-01
Year to date+31.03%USD 1.162025-12-31
1 year-74.69%USD 6.012025-07-31
3 year-99.66%USD 453.002023-08-01
5 year-99.89%USD 1,414.002021-07-30
Since inception-99.96%USD 3,750.002014-05-06

BioVie Financials at a Glance

Market Cap

$11.46MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$19.92M

EPS (TTM)

-$4.27

P/E Ratio

-0.36

Dividend

$0.00

Beta (Volatility)

1.51 (High)

Price

$1.53

Volume

203,811.375

Open

$1.45

Previous Close

$1.52

Daily Range

$1.38 - $1.55

52-Week Range

$1.06 - $6.15

Estimated Earnings Date

Aug 24, 2026

BIVI News

Sick Old Woman in a Wheelchair is Receiving a Help From a Young Nurse in Home Visit

Why Shares of BioVie Jumped This Week

James HalleyMar 10, 2023
Usual day in crowded nursing home

Why Shares of BioVie Jumped 51.7% in February

James HalleyMar 2, 2023
Doctor with senior man_GettyImages-1147479334

Why Shares of BioVie Rose 15.3% in December

James HalleyJan 5, 2023
Alzheimer's - older man looking through window

Why BioVie Stock Is Soaring Today

Keith SpeightsDec 8, 2022
Sick Old Woman in a Wheelchair is Receiving a Help From a Young Nurse in Home Visit

Why BioVie's Shares Tumbled Tuesday

James HalleyDec 6, 2022

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BioVie

BioVie develops medicines for people with serious brain and liver diseases. Its main drugs aim to help those with Alzheimer’s, Parkinson’s, and liver cirrhosis. The company’s treatments target symptoms like memory loss and fluid buildup, aiming to improve daily life.

What’s Cooking in the Lab?

  • NE3107 (bezisterim): Oral drug in late-stage testing for Alzheimer’s and early-stage Parkinson’s; also studied for Long COVID, multiple myeloma, and prostate cancer. (0% of revenue; pre-commercial)
  • BIV201 (terlipressin infusion): Drug for liver cirrhosis-related fluid buildup; completed early trials, preparing for larger studies. (0% of revenue; pre-commercial)
  • Other pipeline assets: Early-stage drugs (NE3291, NE3413, NE3789) for undisclosed uses. (0% of revenue; pre-commercial)

Growth and Expansion: The BioVie Timeline

  • Launched Phase III Alzheimer’s trial for NE3107 in 2023; data review ongoing due to protocol issues.
  • Started new Phase II trial for NE3107 in Parkinson’s disease in April 2025.
  • Secured up to $13.1 million from the U.S. Department of Defense for Long COVID research in 2025.
  • Preparing Phase III trial for BIV201 in a broader liver disease population (2025).
  • Raised $15.7 million in equity and $2.9 million from warrant exercises in the nine months ended March 2025.

What Makes BioVie Stand Out?

BioVie holds patents for its main drugs in the U.S. Europe, and Asia, giving it global protection. The company uses non-dilutive government funding to support research, reducing reliance on shareholder dilution. Its focus on diseases with few treatment options helps it carve out a niche in the biotech sector.

Five Things You Need to Know

  • Revenue was $0 in QQ1 2026, unchanged from QQ1 2025.
  • Net loss was $5 million in QQ1 2026, a 28.2% increase in loss YoY.
  • Operating cash burn was $3 million in QQ1 2026, down 15.5% from QQ1 2025.
  • Cash and equivalents were $23.2 million as of March 31, 2025.

Bottom Line

BioVie remains a pre-revenue biotech focused on late-stage drug development. Its future depends on clinical trial outcomes and continued funding.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

13

CEO

Cuong Viet Do, MBA

Website

www.bioviepharma.com

Headquarters

Carson City, NV 89703, US

BIVI Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-101.09%

Return on Capital

-93.31%

Return on Assets

-113.71%

Earnings Yield

-2.78%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$11.46MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

7.54M

Volume

203.81K

Avg. Volume

166.81K

Financials (TTM)

Gross Profit

-$229.38K

Operating Income

-$20.60M

EBITDA

-$19.71M

Operating Cash Flow

-$20.51M

Capital Expenditure

$0.00

Free Cash Flow

-$20.51M

Cash & ST Invst.

$13.10M

Total Debt

$295.72K

BioVie Performance Analysis

BioVie annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30USD 0N/A
20232023-06-30USD 0N/A
20242024-06-30USD 0N/A
20252025-06-30USD 0N/A
BioVie sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-06-30N/A
Q12025-09-30N/A
Q22025-12-31N/A
Q32026-03-31N/A
BioVie annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30USD -105.77N/A
20232023-06-30USD -154.7146.3%
20242024-06-30USD -73.05-52.8%
20252025-06-30USD -12.12-83.4%
BioVie sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-06-30-21.3%
Q12025-09-3046.2%
Q22025-12-3121.4%
Q32026-03-319.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$57.34K

N/A

Gross Margin

0.00%

N/A

Market Cap

$11.46MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$881.88K

N/A

Employees

13

N/A

Net Income

-$5.27M

-89.0%

EBITDA

-$5.21M

-91.0%

Quarterly Fundamentals

Name
Q3 2026YOY CHG

Total Cash

$13.10M

-43.4%

Total Debt

$295.72K

-19.3%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$213.32K

-27.9%

Short Term Debt

$82.40K

+16.5%

Return on Assets

-1.14%

N/A

Return on Invested Capital

-1.30%

N/A

Free Cash Flow

-$7.44M

-493.7%

Operating Cash Flow

-$7.44M

-493.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GLMDGalmed Pharmaceuticals Ltd.
$0.62+3.67%
INMInMed Pharmaceuticals Inc.
$1.47-2.00%
KZIAKazia Therapeutics Ltd ADR
$12.62-1.56%
ARTLArtelo Biosciences, Inc.
$0.77+1.96%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About BIVI

What is the current price of BioVie?

BioVie is trading at $1.52 per share.

What is the 52-week range for BioVie?

Over the past 52 weeks, BioVie has traded between $1.06 and $6.15.

How much debt does BioVie have?

As of the most recent reporting period, BioVie reported total debt of $295.72K.

How much cash does BioVie have on hand?

BioVie reported $13.10M in cash and cash equivalents in its most recent financial results.

What is BioVie’s dividend yield?

BioVie does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services